The Federal Government Just Fact-Checked the Anti-Weed Argument
Its own survey shows teen use falling as legalization spreads. Meanwhile a governor warns the hemp ban could cost 3,500 jobs, and Rhode Island is refunding a licensing mess that never should have happ
For years the case against cannabis reform rested on three confident predictions. Legalization would send teen use through the roof. Higher possession limits would feed the illicit market. And hemp products were just a temporary loophole you could close without anyone getting hurt.
This week, the evidence quietly took a wrecking ball to all three.
A new federal survey shows teen marijuana use still falling even as adult markets expand. Vermont’s top regulator says doubling the possession limit might actually pull people toward licensed stores. And Wisconsin’s governor is warning that the November hemp ban could wipe out hundreds of millions in economic activity and thousands of jobs.
The thread running through all of it isn’t really legalization anymore. It’s whether our institutions are measuring the right things, or just repeating old assumptions. The data is starting to write the policy now, and the slogans are running out of gas. Let me walk you through it.
The government’s own survey just gutted the “think of the children” argument.
One of the oldest arguments against legalization is getting really hard to keep making with a straight face. New results from the federal National Survey on Drug Use and Health show 8.7% of teens ages 12 to 17 used marijuana in the past year in 2025. Back in 2011, the year before Colorado and Washington legalized, that number was 14.2%. Past-month teen use dropped too, from 6.1% in 2021 to 5% in 2025. Meanwhile adult use went the other way, with more than 61 million Americans reporting cannabis use in the past year.
Let me be careful, because correlation isn’t causation and I won’t pretend otherwise. Teen behavior is shaped by a hundred things, education, parents, product trends, broader shifts in how kids use substances generally. This survey doesn’t prove legalization caused the decline.
But it absolutely demolishes the specific prediction that opening licensed adult stores would send teen use soaring. That just didn’t happen, and the government’s own data says so. And the “why” is worth sitting with, because it’s a little counterintuitive. Regulated retailers check IDs. Licensed products move through age-gated channels. Your local illegal dealer has never once asked for a birthday. There’s also a decent argument that legalization strips away some of weed’s rebellious cool by turning it into a boring adult purchase, like buying a six-pack. One caution for operators, though: this is not a green light to get lazy on youth protections. Advertising, packaging, and online marketing are still political powder kegs, and any company that blurs the line toward youth appeal hands ammunition to the entire industry’s opponents.
The bottom line: Legalization expanded adult access without the teen-use surge everyone was warned about. The strongest reform argument isn’t a theory anymore, it’s in the federal government’s own spreadsheet.
Wisconsin’s governor is warning the hemp ban is an economic bomb, not a policy tweak.
Wisconsin Governor Tony Evers is pushing Congress to stop the federal recriminalization of most hemp-derived THC products before it hits November 12. Under the pending standard, legal hemp gets capped at 0.4mg of total THC per container, low enough to erase most intoxicating beverages, edibles, and a lot of full-spectrum products. Evers says the restriction puts more than $700 million in Wisconsin economic activity, at least 3,500 jobs, and hundreds of licensed producers at risk. He wants Congress to build a science-based system instead, with research, crop insurance, and financial access attached.
Here’s what makes this more than a cannabis story. It’s an agriculture and credit problem now. Farmers decide what to plant months ahead of harvest. Manufacturers buy equipment and sign leases betting on what’ll be legal. Retailers lock in contracts long before anything hits a shelf. So a rule that technically starts in November is already doing damage today, through every decision being frozen or canceled right now. Banks and lenders should already be sweating concentration risk, because any company that leans heavily on hemp THC revenue could be staring at sudden inventory writeoffs and cash-flow trouble if Congress sits on its hands.
The politics here are especially sharp, and honestly a little absurd. Wisconsin hasn’t legalized medical or recreational marijuana, so hemp products are one of the only legal cannabinoid markets its residents and businesses actually have. And the state’s about to lose even that. Look, regulation is genuinely warranted. Age limits, testing, labeling, potency standards, all reasonable, all overdue. But wiping out the entire market with an impossibly low per-container cap isn’t product regulation. It’s prohibition wearing a regulation costume.
The bottom line: The hemp deadline stopped being hypothetical a while ago. Farmers and lenders are making calls right now, and Congress is one delay away from turning uncertainty into layoffs and distressed inventory.
Vermont doubled its possession limit on purpose, as a shot at the illicit market.
Vermont doubled how much cannabis adults can legally carry, up to two ounces of marijuana or ten grams of hashish. James Pepper, who chairs the Vermont Cannabis Control Board, frames it as a way to move people out of the illicit market and into regulated stores by scrapping a criminal restriction that never made much sense.
And the law does a lot more than bump up the possession number. It lets the governor negotiate future interstate cannabis deals if federal policy shifts, creates a pilot for cannabis sales at events, cuts some cultivation fees, kills the vertically integrated license category, and protects tenants from lease clauses banning simple possession at home (landlords can still ban smoking, just not possession).
That interstate-commerce piece is the one I’d watch most closely, and I’ve flagged it before because it’s such a big deal. Right now every state is a cannabis island. Product grown in one state generally can’t legally cross into another, even when both have regulated markets, which forces every single state to build its own cultivation and manufacturing from scratch whether the economics make sense or not. Regional trade would blow that open, letting low-cost producers serve nearby markets while states coordinate on standards. That’s a fundamentally more rational economy than the one we’ve got. And the event-sales pilot is a nice nearer-term win for small growers, who usually struggle to build a brand because customers only ever deal with the dispensary, not the farm. Selling direct at licensed events gives independent operators a real path to market without forcing them to vertically integrate.
The bottom line: Vermont is treating the illicit market like a business competitor to out-compete, not a crime to arrest away. Higher limits, lower fees, and future interstate trade are all aimed at making the legal option the easier one.
Rhode Island is refunding a licensing disaster, and the refund doesn’t come close to covering the damage.
Rhode Island regulators are returning $7,500 application fees to 75 would-be cannabis retailers after litigation forced the state to scrap and restart its whole licensing process. The original round had 97 applicants fighting for 20 retail licenses, until a federal court halted it because Rhode Island required businesses to be majority-owned by state residents, which got challenged as unconstitutional discrimination against interstate commerce. Lawmakers pulled the residency rule, voided the round, and told regulators to start over. Everyone has to reapply.
Here’s the part that should bother you, because the refund is almost beside the point. Rhode Island makes applicants control real estate and get local zoning approval before they even apply. So some of these businesses were paying rent, lawyers, consultants, and architects the entire time the process sat frozen. Getting $7,500 back doesn’t touch months of carrying costs, and the annual license fee for winners is $30,000 on top of it.
For a well-funded multistate operator, months of dead rent and legal bills is an annoyance. For a social-equity or small-business applicant, it can be the whole ballgame, the thing that drains their savings before they ever open a door. That’s the quiet way licensing design decides who actually gets to participate. Rhode Island’s instinct to protect local ownership was politically understandable but legally shaky, and there’s a better way to do it, focusing equity policy on prior enforcement, income, community impact, and capital access without explicitly shutting out everyone from across state lines. And landlords, take note: leases with cannabis applicants need licensing contingencies and delayed rent commencement built in, or regulatory litigation traps everybody.
The bottom line: Refunding $7,500 is the right move, but it doesn’t reimburse months of rent and legal fees. Licensing design is what decides whether social equity is real or just an expensive application to fill out.
Congress wants hospitals to check whether their drug tests actually detect the thing that’s killing people.
A House committee unanimously approved Tyler’s Law, which directs federal health officials to study how ERs test overdose patients for fentanyl, marijuana, and other drugs. It’s sponsored by Rep. Ted Lieu and named for Tyler Shamash, a 19-year-old who died after ingesting fentanyl but wasn’t tested for it when he showed up with a suspected overdose. The bill would have HHS study how often hospitals actually test for fentanyl, what it costs, and how routine testing affects privacy and care. It cleared the Energy and Commerce Committee 46 to 0.
That case exposes a real weakness in a lot of standard drug screens. A hospital might test for broad buckets like marijuana, cocaine, or opiates and completely miss fentanyl, the one substance actually causing the emergency in front of them. That’s backwards.
And cannabis adds its own wrinkle here that’s worth understanding. THC metabolites can linger for weeks after any high wears off. So a positive result doesn’t prove cannabis caused the crisis, impaired the patient, or had anything to do with why they’re in the ER. If a clinician misreads that, it distorts the medical record, reinforces stigma, and can quietly shape how the patient gets treated, all off a result that may be clinically meaningless. The fallout is practical too, lab upgrades, new protocols, staff education, and hospitals reviewing what’s even on their standard panels and whether their people understand what each result does and doesn’t mean.
The bottom line: Better ER testing saves lives, but more testing isn’t automatically better medicine. The goal is finding the substance causing the crisis, not letting an incidental weed result become the headline.
Cancer survivors are already using CBD, with or without their doctors in the loop.
Nearly one in five cancer survivors reports using CBD after diagnosis, mostly for pain, sleep problems, emotional distress, and neuropathy, and more than half said it gave them at least some relief.
I’ll repeat the caution the researchers gave, because it matters: this does not show CBD treats cancer, and nobody should read it that way. Cannabinoids are not a replacement for oncology care, full stop.
What it does show is that patients are folding CBD into their supportive care whether or not their hospital or physician is ready to talk about it. And that creates a real communication gap. Patients often assume CBD is harmless simply because it’s sold everywhere. Clinicians often dodge the topic because product quality is all over the place, dosing standards barely exist, and most of them never got trained on cannabinoids. But here’s the thing, staying silent doesn’t stop patients from using it. It just leaves them making the call alone, with no professional guidance.
The sensible response for health systems isn’t a thumbs-up or a thumbs-down. It’s routine screening for cannabinoid use, honest conversations about interactions, and documenting what people are actually taking. And for operators, selling into a medically vulnerable population comes with a higher bar. Unsupported cancer claims, inconsistent formulations, and vague labeling are the fastest possible route to regulatory enforcement and reputational damage. Over time the smart money probably favors the companies offering standardized dosing, independent testing, and real clinical data over the ones making fuzzy wellness promises.
The bottom line: CBD is already part of cancer survivorship in practice. The only question is whether the medical system engages with evidence and safety, or leaves the whole conversation to product marketing.
The White House and Congress agree hemp needs saving. They don’t agree on what to save.
That bipartisan hemp bill keeps getting described as having White House support, but administration officials reportedly have real concerns about the provisions covering inhalable products. The bill from Reps. Andy Barr and Angie Craig would reverse much of the November 12 restriction and swap in taxes, licensing, age controls, and product standards.
The fight here isn’t over whether Congress should act on the coming disruption. It’s over which products actually deserve to survive, and that distinction could decide the fate of flower, vapes, beverages, edibles, and full-spectrum CBD all differently.
The administration seems more comfortable protecting regulated ingestible products than inhalable hemp. To a lawmaker, carving out inhalables might look like a safe political compromise. To a business, it’s the difference between living and dying, depending entirely on what you happen to make. A company built around vapes or hemp flower could face total collapse while a beverage company gets a clean regulated runway. So please, do not treat “hemp reform” as one unified thing that either happens or doesn’t. Product format is about to matter as much as cannabinoid content. And this is a great lesson in the danger of legislative branding, because “the White House supports my bill” and “the White House agrees with the actual text that decides who survives” are very different statements, and only one of them pays your rent.
The bottom line: Congress might save part of the hemp market without saving all of it. Businesses need to study their exact product category, not lean on a vague promise that a fix is coming.
Alcohol distributors will back THC drinks, as long as they own the pipes.
The Wine & Spirits Wholesalers of America is backing federal legislation to keep hemp-derived THC beverages legal, favoring age limits, testing, licensing, and a three-tier distribution system modeled on alcohol. They’re less thrilled about the proposed taxes, including a five-cent-per-milligram THC charge plus an extra manufacturer tax.
I flagged the alcohol industry’s shift last edition, and this fills in the fine print, which is where it gets interesting. The endorsement matters because it means major alcohol interests have stopped seeing THC drinks purely as a threat and started seeing a category they can distribute, regulate, and make money on. That’s a big tailwind for the survival of the category.
But institutional support always arrives with institutional architecture attached, and that’s the catch. The three-tier system splits manufacturers, wholesalers, and retailers apart. It brings national infrastructure and political credibility, sure. It could also force small beverage brands to hand over margin and control to the big established distributors. So for independent hemp companies, alcohol-industry backing is both a lifeline and a warning at the same time. The category may well survive federal prohibition, just under rules written by, and favoring, the larger incumbents. And watch the tax fight closely, because a five-cent-per-milligram tax sounds tiny until you stack it on top of state excise taxes, distributor margins, and retail markup, at which point legal drinks may struggle to compete with the unregulated stuff on price.
The bottom line: THC beverages are entering mainstream alcohol policy, which boosts their odds of surviving. But the next fight is over distribution power, taxes, and who controls the door to the retail shelf.
Final thought
For decades, cannabis policy ran on predictions. Teen use would explode. Legal markets would fail. Possession reform would drive up crime. Hemp was economically trivial. Patients couldn’t be trusted. All of it got baked into law long before anyone had real data.
Now the data’s showing up, and it keeps disagreeing with the predictions. Teen use fell during the legalization era. States are finding that sensible possession limits and affordable licensing might help legal businesses actually beat illicit sellers. Governors are putting hard numbers on what hemp prohibition would cost in jobs and investment. Hospitals are realizing that a substance showing up on a drug screen isn’t the same as that substance mattering. And the old-guard industries have stopped arguing about whether THC markets will exist and started negotiating taxes and distribution instead.
That’s what normalization actually looks like. Not everybody suddenly approving. Not risk disappearing. Just assumptions getting quietly replaced by operating facts. The next era of policy belongs to the institutions that can move quickly once the facts are in, and honestly the same goes for businesses. The operators who win won’t be the ones betting on slogans or political promises. They’ll be the ones tracking product-specific rules, structuring their leases around licensing risk, getting ready for interstate trade, and building compliance into strategy from day one.
The culture war is fading. The market-reality era is here.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.